Risk for Mortality in High versus Low Antiparkinsonian Therapy Dose During the First Year of Parkinson's Disease: A Real-World Study.
Antiparkinson’s agents
Drug dosage calculations
Mortality
Parkinson’s disease
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
08 Jul 2024
08 Jul 2024
Historique:
received:
08
04
2024
accepted:
06
06
2024
medline:
8
7
2024
pubmed:
8
7
2024
entrez:
8
7
2024
Statut:
aheadofprint
Résumé
Early, simple predictors for long-term survival in Parkinson's disease (PD) may help identify patients at elevated risk and are crucial for more personalized treatment. This large, retrospective study examined whether higher levodopa equivalent daily dose (LEDD) a year after diagnosis predicts long-term survival. Mortality risk was increased among 292 patients receiving ≥ 600 mg LEDD versus 2233 patients receiving < 600 mg LEDD (hazard ratio 1.5; 95% confidence interval 1.3-1.7), particularly among patients aged < 75 years (1.8; 1.4-2.4). In PD, higher LEDD can be an early risk marker of increased mortality, probably because it reflects more severe disease.
Identifiants
pubmed: 38976124
doi: 10.1007/s12325-024-02924-8
pii: 10.1007/s12325-024-02924-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Greenland JC, Williams-Gray CH, Barker RA. The clinical heterogeneity of Parkinson’s disease and its therapeutic implications. Eur J Neurosci. 2019;49(3):328–38. https://doi.org/10.1111/ejn.14094 .
doi: 10.1111/ejn.14094
pubmed: 30059179
Macleod AD, Taylor KS, Counsell CE. Mortality in Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014;29(13):1615–22.
doi: 10.1002/mds.25898
pubmed: 24821648
Bloem BR, Okun MS, Klein C. Parkinson’s disease. Lancet. 2021;397(10291):2284–303.
doi: 10.1016/S0140-6736(21)00218-X
pubmed: 33848468
Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord. 2010;25(15):2649–53.
doi: 10.1002/mds.23429
pubmed: 21069833
Barer Y, Gurevich T, Chodick G, et al. Advanced-stage Parkinson’s disease: from identification to characterization using a nationwide database. Mov Disord Clin Pract. 2022;9(4):458–67.
doi: 10.1002/mdc3.13458
pubmed: 35586537
pmcid: 9092754
Antonini A, Stoessl AJ, Kleinman LS, et al. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country Delphi-panel approach. Curr Med Res Opin. 2018;34(12):2063–73.
doi: 10.1080/03007995.2018.1502165
pubmed: 30016901
Parkinson Study Group. Levodopa and the progression of Parkinson’s disease. NEJM. 2004;351(24):2498–508.
doi: 10.1056/NEJMoa033447
Shalev V, Chodick G, Goren I, Silber H, Kokia E, Heymann AD. The use of an automated patient registry to manage and monitor cardiovascular conditions and related outcomes in a large health organization. Int J Cardiol. 2011;152(3):345–9.
doi: 10.1016/j.ijcard.2010.08.002
pubmed: 20826019
Chodick G, Heymann AD, Shalev V, Kookia E. The epidemiology of diabetes in a large Israeli HMO. Eur J Epidemiol. 2003;18(12):1143–6.
doi: 10.1023/B:EJEP.0000006635.36802.c8
pubmed: 14758871
Weitzman D, Chodick G, Shalev V, Grossman C, Grossman E. Prevalence and factors associated with resistant hypertension in a large health maintenance organization in Israel. Hypertension. 2014;64(3):501–7.
doi: 10.1161/HYPERTENSIONAHA.114.03718
pubmed: 24958503
Coresh J, Turin TC, Matsushita K, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA. 2014;311(24):2518–31.
doi: 10.1001/jama.2014.6634
pubmed: 24892770
pmcid: 4172342
Ben Zaken S, Radomysky Z, Koren G. Association between serum magnesium levels and Alzheimer’s disease or mixed dementia patients: a population-based retrospective controlled study. J Alzheimers Dis Rep. 2020;4(1):399–404.
doi: 10.3233/ADR-200220
pubmed: 33163901
pmcid: 7592834
Hoogland J, Post B, de Bie R. Overall and disease related mortality in Parkinson’s disease–a longitudinal cohort study. J Parkinson’s Dis. 2019;9(4):767–74.
doi: 10.3233/JPD-191652
Bugalho P, Ladeira F, Barbosa R, et al. Motor and non-motor function predictors of mortality in Parkinson’s disease. J Neural Transm (Vienna). 2019;126(11):1409–15.
doi: 10.1007/s00702-019-02055-3
pubmed: 31385098
Breen DP, Evans JR, Farrell K, Brayne C, Barker RA. Determinants of delayed diagnosis in Parkinson’s disease. J Neurol. 2013;260:1978–81.
doi: 10.1007/s00415-013-6905-3
pubmed: 23572347
Alves G, Larsen JP, Emre M, Wentzel-Larsen T, Aarsland D. Changes in motor subtype and risk for incident dementia in Parkinson’s disease. Mov Disord. 2006;21(8):1123–30.
doi: 10.1002/mds.20897
pubmed: 16637023
Latourelle JC, Beste MT, Hadzi TC, et al. Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson’s disease: a longitudinal cohort study and validation. Lancet Neurol. 2017;16(11):908–16.
doi: 10.1016/S1474-4422(17)30328-9
pubmed: 28958801
pmcid: 5693218